After shedding its cancer business just over a decade ago, GSK's new CEO is building back with a $10.6 billion deal
葛兰素史克(US:GSK) WSJ·2026-06-10 09:00公司战略动向 - GSK正在通过一项价值106亿美元的交易重建其肿瘤学业务 [1] - 该公司在十余年前剥离了其肿瘤业务 [1] 行业并购活动 - 制药行业出现一笔金额达106亿美元的重大并购交易 [1]